On Monday, MGIC Investment Corp. (NYSE:MTG)’s shares surged 1.31% to $10.02, after MGIC Investment issued an Operational Summary of its insurance auxiliaries for the month of March 2015 for their primary mortgage insurance.
The information concerning new notices and cures is compiled from reports received from loan servicers. The level of new notice and cure activity stated in a particular month can be influenced by, among other things, the date on which a servicer generates its report, the number of business days in a month, and by transfers of servicing between loan servicers.
MGIC Investment Corporation, through its auxiliaries, provides private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States.
HSBC Holdings plc (NYSE:HSBC)’s shares gained 1.30% to $45.27, during the last trading session on Monday, after Kyriba, the global leader in cloud-based treasury administration solutions, has accomplished a $21 million round of Series C funding. Kyriba will use these funds for product innovation and to support the company’s rapid global expansion. Kyriba enables nearly 1,000 companies worldwide to optimize their cash, manage their risk and better work their capital.
Through its planned investments program, HSBC (NYSE: HSBC) joins existing investors BRED Banque Populaire, Daher Capital, Iris Capital and Upfront Ventures to support Kyriba’s global expansion.
HSBC Holdings plc provides banking and financial products and services. It operates through four businesses Retail Banking and Wealth Administration, Commercial Banking, Global Banking and Markets, and Global Private Banking.
At the end of Monday’s trade, Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s shares gained 1.30% to $15.63, after a biotechnology company, declared the appointment of Harry J. Leonhardt, Esq., as senior vice president, general counsel and chief compliance officer, reporting to Dr. Helen Torley, president and chief executive officer.
Mr. Leonhardt brings more than 30 years of corporate legal, intellectual property, compliance, business development and mergers and attainments experience to Halozyme, with an extensive background in the biotechnology sector. He most recently served as senior vice president of Legal and Compliance, and corporate secretary for Amylin Pharmaceuticals, a biotech company attained by Bristol Myers Squibb in 2012. At Halozyme, he will be responsible for all legal, compliance and intellectual property matters.
Preceding to joining Amylin, Mr. Leonhardt served as senior vice president, general counsel and corporate secretary for Senomyx; executive vice president of Business Development, general counsel and corporate secretary at Genoptix, Inc.; and senior vice president, general counsel and secretary for Nanogen, Inc. He also held positions of increasing responsibility at Allergan, Inc. counting head of worldwide litigation and general counsel for European Operations. Early in his career, Mr. Leonhardt was an attorney at the Los Angeles office of Lyon & Lyon where he represented a number of prominent clients in the biotechnology and pharmaceutical industries. He received his Bachelor of Science degree from the University of the Sciences in Philadelphia and his Juris Doctorate from the University of Southern California Law Center.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
Finally, Cowen Group, Inc. (NASDAQ:COWN), ended its Monday’s trading session with 1.27% gain, and closed at $5.59, after a publicly owned asset administration holding company declared that its Board of Directors has designated Douglas A. Rediker as an independent director of the firm, effective right away.
Mr. Rediker’s appointment expands the Board to eight directors, six of whom are independent.
Mr. Rediker presently serves as the Executive Chairman of International Capital Strategies, a political economy consulting firm he founded in 2012. He is also a Visiting Fellow at the Peterson Institute for International Economics. From 2010 to 2012, Mr. Rediker represented the U.S. on the Executive Board of the International Monetary Fund (IMF). From 2011-2012, he served as the chairman and vice chairman of the World Economic Forum (WEF) Geopolitical Risk Global Agenda Council and presently serves as a member of the WEF’s Geo-economic Global Agenda Council.
Formerly, Mr. Rediker lived and worked in Europe for 16 years as a senior investment banker with Dresdner Kleinwort, Lehman Brothers, Merrill Lynch and Salomon Brothers and as a private equity investor with TD Capital. He began his career as an attorney at Skadden Arps.
He also served as Senior Fellow at the New America Foundation and director of the Global Planned Finance Initiative, which he cofounded. He is a member of the US Council on Foreign Relations.
Mr. Rediker has testified before the US Congress on subjects such as the role of the IMF, foreign policy implications of the economic crisis, and the threats and opportunities posed by sovereign wealth funds and state capitalism. He is coeditor of the e-book, What’s Next: Essays on the Geopolitics That Matter. He has published opinion pieces in the Financial Times, New York Times, Foreign Policy, New Republic, Wall Street Journal, Forbes, Fortune, Globalist, European Affairs, and National Interest and has appeared on a regular basis on the BBC, CNN, CNBC, and PBS. He was named an “Emerging Markets Superstar” by Global Finance Magazine and has received both the “EEMEA Equity” and “M&A Deals of the Year” by the International Financing Review.
Mr. Rediker graduated from Vassar College with an A.B. in political science and received a Juris Doctor from Fordham University School of Law.
Cowen Group, Inc. is a publicly owned asset administration holding company. Through its auxiliaries, the firm provides alternative investment administration, investment banking, research, and sales and trading services for its clients. It manages separate client focused portfolio through its auxiliaries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
